Global Cervical Cancer Diagnostic Testing Devices Market Size Worth USD 10.75 Billion by 2026 at 4.5% CAGR - Report by Credible Markets Research (CMR)

February 22, 2022, New York, USA -

Cervical Cancer Diagnostic Testing Devices: Introduction

Cervical cancer refers to the abnormal growth of cancerous or malignant cells within the cervix area of women. It is a problem for the entrance of the womb, i.e., the entry into the uterus via the vagina. Over 90 percent of cervical cancers occur because of human papillomavirus (HPV virus) and are diagnosed by the smear test.

The most prevalent kinds of cervical cancers are Adenocarcinoma and squamous cell carcinomas. The HPV vaccine, as well as the diagnostic as well as treatment for cancerous lesions, may aid in preventing cervical cancer. The typical symptoms of cervical cancer are vaginal bleeding and the foul smells associated with it. Cervical cancer diagnosis consists of tests like the Pap test, HPV tests, Colposcopy, Imaging studies and many more.

The Global Cervical Cancer Diagnostic Testing Devices Market Forecast: 

Cervical Cancer Diagnostics Market was valued at USD 7.5 Billion in 2018 and is projected to reach USD 10.75 Billion by 2026, growing at a CAGR of 4.5% from 2019 to 2026.

The Global Cervical Cancer Diagnostic Testing Devices Market Overview: 

The increasing public-private investment and the increase in the ageing females, increasing awareness regarding the need for prevention, and technological advancements are among the main elements that will drive the growth of the global cervical cancer diagnostics market. Cancer awareness programs aid in the expansion of the market.

Additionally, the growing demand for novel treatments and biomarkers to enhance screening results is anticipated to drive the market's expansion. However, the high operating costs that are associated with manufacturing, as well as over-diagnosis and treatment and complicated tests, are reasons that may slow the growth of the market.

Key Market Insights: 

Cervical cancer is one of the types of cancer that is caused by the uncontrolled growth of cells. The risk of developing cervical cancer is linked to HPV or human papillomavirus (HPV) infection in the cervix. As per WHO figures, cervical cancer ranks fourth in the top five most frequently occurring cancers in women, with around 570,000 new cases diagnosed in 2018.

The rising incidence of cancers in the cervical area has led to a greater need for cervical cancer diagnosis screening tests for women. A cervical cancer diagnosis is an essential part of a woman's regular health and could aid in the treatment of cervical cancer. In general, the tests for diagnosing cervical cancer consist of two types: HPV test and Pap test.

When performing the Pap test, the cells of the cervix are removed to be stained and analyzed for any abnormalities.

Click Here to Get More Information: https://crediblemarkets.com/sample-request/cervical-cancer-diagnostic-testing-devices-market-81043

The HPV test cells, the cells from the cervix, can be examined for signs of infection due to HPV.

A growing number of women are taking cervical cancer diagnostic tests because of the increased awareness. The government also plays an essential role by arranging healthcare camps for women, free of charge, insurance and education programs. It has also led to a rise in the number of cancer diagnosis centers and service providers. This is expected to help the growth in the cervical cancer diagnostics industry.

The market for cervical cancer diagnostics in the world's development is caused by the rise in the incidence of cancers in the cervical cavity, rising in the geriatric female population, as well as advances in cervical cancer diagnosis.

Additionally, favorable reimbursement for health and active support from the government and a growing concern for women's health are a number of major reasons which are likely to boost the market for cervical cancer diagnostics. Based on GLOBOCAN 2018, the incidence of cervical cancer has been predicted to rise from 569,847 to 642,421 by the year 2025. This is expected to drive the market for cervical cancer diagnostics.

But, the absence of qualified professionals and the lack of availability of cervical cancer diagnostic tests are among the most significant factors that hinder the expansion of the global cervical cancer diagnostic market.

The Key Market Segmentation of the Global Cervical Cancer Diagnostic Testing Devices Market: 

Global Cervical Cancer Diagnostic Testing Devices Market can be divided into Test Types, Age Group, End-User, Geographical landscapes, etc. 

Cervical Cancer Diagnostic Testing Devices Market Segmentation By Test Type:

Pap testing (Cytology testing)

HPV Testing

Colposcopy

Cervical Biopsies

Cystoscopy

Cervical Cancer Diagnostic Testing Devices Market Segmentation By Age Group:

20-40 Years

Above 40 Years

Cervical Cancer Diagnostic Testing Devices Market Segmentation By End-Users:

Hospitals and Clinics

Specialty Clinics

Diagnostic Laboratories

Diagnostic Imaging Centers

Research Institutes

Cervical Cancer Diagnostic Testing Devices Market Segmentation By Geographical Landscape:

North America

Europe

Asia Pacific

South America

Middle East and Africa 

Major Key Players in the Global Cervical Cancer Diagnostic Testing Devices Market Are:

• Hologic Corporation
• Dickinson and Company (BD)
• Qiagen N.V.
• Siemens Healthcare
• Becton, 
• Abbott Laboratories, 
• Guided Therapeutics, Inc.
• Quest Diagnostics, Hologic Inc., 
• Ascon Medical Instruments Pvt Ltd
• Hoffmann-La Roche Ltd
• OncoHealth Corp., 
• Arbor Vita, 
• Cooper Surgical Inc.
• Cardinal Health, Inc.
• Beckman Coulter Inc.

The Covid-19 Impact Analysis:

Due to the emergence of COVID-19, the market witnessed a slowdown in terms of growth. As the number of COVID-19 cases increased and the healthcare system changed its focus to stopping the disease, leading to delays in the diagnosis and treatment for other chronic illnesses such as cancer. This means that a negative impact is expected to be felt on the market for cancer diagnostics because of the pandemic situation. In the coming years, substantial growth is anticipated in cancer diagnostic procedures. 

Contact Us

Credible Markets Analytics
99 Wall Street 2124 New York, NY 10005
Contact:  +1(929)-450-2887
Email: [email protected]